Maxim Group Reaffirms “Hold” Rating for CNS Pharmaceuticals (NASDAQ:CNSP)

Maxim Group reissued their hold rating on shares of CNS Pharmaceuticals (NASDAQ:CNSP) in a report issued on Tuesday morning,Benzinga reports.

Separately, Alliance Global Partners upgraded CNS Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 24th.

CNS Pharmaceuticals Stock Performance

Shares of CNS Pharmaceuticals stock opened at $1.63 on Tuesday. The stock has a 50 day moving average of $4.10 and a 200 day moving average of $5.43. The firm has a market capitalization of $1.87 million, a price-to-earnings ratio of -0.02 and a beta of 2.65. CNS Pharmaceuticals has a fifty-two week low of $1.28 and a fifty-two week high of $975.00.

Hedge Funds Weigh In On CNS Pharmaceuticals

Several large investors have recently made changes to their positions in the stock. Geode Capital Management LLC increased its holdings in CNS Pharmaceuticals by 90.5% in the 4th quarter. Geode Capital Management LLC now owns 387,064 shares of the company’s stock valued at $47,000 after purchasing an additional 183,884 shares during the last quarter. Wealthfront Advisers LLC acquired a new position in CNS Pharmaceuticals during the fourth quarter worth $26,000. Integrated Wealth Concepts LLC purchased a new position in shares of CNS Pharmaceuticals during the fourth quarter worth $30,000. Connective Capital Management LLC acquired a new stake in shares of CNS Pharmaceuticals in the fourth quarter valued at $34,000. Finally, XTX Topco Ltd purchased a new stake in shares of CNS Pharmaceuticals in the 4th quarter valued at $36,000. 14.02% of the stock is currently owned by institutional investors and hedge funds.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.